Point-of-Care Viscoelastic Testing System Supports Obstetric Bleeding Management

HemoSonics (Durham, NC, USA) announced on May 5, 2026 that the company's Quantra Hemostasis System for Obstetric Procedures won Silver in the 2026 Edison Awards in the Women’s Health and Reproductive Innovations category. The platform is the first and only viscoelastic testing (VET) system cleared by the U.S. Food and Drug Administration (FDA) for obstetric bleeding. It delivers rapid, point-of-care coagulation insights intended to help protect women at risk of peripartum hemorrhage by providing clinicians with actionable data.

The Quantra platform comprises the Quantra Hemostasis Analyzer and QPlus and QStat Cartridges. It uses SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound-based method that measures the coagulation properties of a whole-blood sample. Results are typically available in less than 15 minutes to support individualized, evidence-based decisions and patient blood management at the point of need.

Image: The HemoSonics Quantra Hemostasis System provides comprehensive blood analysis, delivering rapid, real-time coagulation insights at the point of need. Quantra is the first and only cartridge-based, FDA-cleared viscoelastic testing (VET) platform for obstetrics. (Photo courtesy of HemoSonics)

The QStat Cartridge received 510(k) clearance in August 2025 for expanded use in peripartum obstetric procedures, extending the system’s application to obstetric bleeding. This clearance makes Quantra the only cartridge-based VET platform cleared for obstetrics. The system is described as easy to operate and maintain and provides comprehensive whole-blood coagulation analysis at the point of need.

Postpartum hemorrhage remains the leading cause of maternal mortality worldwide, affecting more than 14 million women annually and contributing to an estimated 70,000 deaths each year. In the United States, maternal mortality stands at 21.1 deaths per 100,000 live births, with obstetric bleeding accounting for more than 10% of cases. 

“HemoSonics is committed to fighting maternal mortality caused by severe bleeding, which is why we are particularly proud to receive the Silver award at the 2026 Edison Awards in the Women’s Health and Reproductive Innovations category,” said Francesco Viola, Founder and Chief Scientific Officer, HemoSonics.

“After the recent expansion of the Quantra Hemostasis System to the obstetric population, a growing number of top hospitals in the U.S. are using our technology to help women have safe and healthy deliveries, by empowering clinicians with actionable data when and where it’s needed,” added Viola.

Related Links
HemoSonics